We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for Olutasidenib (Dr Reddys Laboratories Australia Pty Ltd)
Active ingredients
Olutasidenib
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
capsule
Indication
Treatment of patients with IDH1 mutated acute myeloid leukaemia
Therapeutic area
Haematology